Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 3

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 3
---
 table commencing on page 10. We will not receive any proceeds from the sale of the common shares by the selling shareholders. All net proceeds from the sale of the common shares covered by this prospectus will go to the selling shareholders. However, we may receive the proceeds from any exercise of warrants if the selling shareholders do not exercise the warrants on a cashless basis, if and when exercised. See “Use of Proceeds.”

The selling shareholders
may sell all or a portion of the common shares from time to time in market transactions through any market on which our common shares
are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market
price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such
methods of sale. We will bear all of the expenses incurred in connection with the registration of these shares. The selling shareholders
will pay any underwriting discounts and selling commissions and/or similar charges incurred in connection with the sale of the shares.
See “Plan of Distribution”.

Our Common Shares are currently traded on the Nasdaq Capital Market,
or Nasdaq, under the symbol “CMND.” On March 12, 2025, the last reported sale price of our Common Shares on the Nasdaq was
$1.13.

Our Common Shares also trade on the Frankfurt Stock Exchange, or
FSE, under the symbol “CWY”. On March 12, 2025, the last reported sales price of our Common Shares on FSE was EUR 0.99 (approximately
$1.08) per share.

We
are both an emerging growth company, as defined in the Jumpstart Our Business Startups Act
of 2012 (or the JOBS Act), and a “foreign private issuer,” as defined under the
U.S. federal securities law and are subject to reduced public company reporting requirements.
See “Prospectus Summary – Implications of Being an Emerging Growth Company and
Foreign Private Issuer” for additional information.

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 5.

Neither the Securities and Exchange Commission, or the SEC, nor the Canadian Securities Exchange, nor any state or other foreign securities commission has approved nor disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus